Liñares Antonio, Dopico Jose, Blanco Carlota, Pico Alex, Sobrino Tomás, Blanco Juan, Leira Yago
Periodontology Unit, Faculty of Odontology, University of Santiago de Compostela, Santiago de Compostela, Spain.
NeuroAging Research Group, Clinical Neurosciences Research Laboratories, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.
Clin Oral Implants Res. 2024 Dec;35(12):1519-1530. doi: 10.1111/clr.14339. Epub 2024 Aug 2.
The aim of this study was to evaluate the systemic effect of non-surgical peri-implantitis treatment (NSPIT) with or without the administration of systemic metronidazole.
In this secondary analysis from a previously published clinical trial (NCT03564301), peri-implantitis patients were randomized into two groups: test, receiving NSPIT plus 500 mg of oral systemic metronidazole three times a day for 7 days (n = 10); and control group, receiving NSPIT plus placebo (n = 11). Serum samples were obtained at baseline, 3 and 6 months after therapy to determine levels of inflammatory biomarkers, lipid fractions and complete blood counts.
Both treatment modalities produced improvements in clinical and radiographic parameters. After 6 months from NSPIT, a substantial reduction in C-reactive protein (6.9 mg/dL; 95% CI: 3.7 to 9.9, p < .001) and low-density lipoprotein cholesterol (21.8 mg/dL; 95% CI: -6.9 to 50.5, p = .013) as well as a modest increase in neutrophils counts (0.4 × 10/μL; 95% CI: -0.4 to 1.1, p = .010) was observed in the control group while the test group showed a significant reduction of TNF-α (110.1; 95% CI: 38.9 to 181.4, p = .004).
NSPIT showed a short-term beneficial systemic effect regardless of adjunctive use of systemic metronidazole.
本研究旨在评估非手术性种植体周炎治疗（NSPIT）联合或不联合全身应用甲硝唑的全身效果。
在这项对先前发表的一项临床试验（NCT03564301）的二次分析中，种植体周炎患者被随机分为两组：试验组，接受NSPIT治疗并每天口服500毫克全身用甲硝唑3次，共7天（n = 10）；对照组，接受NSPIT治疗并服用安慰剂（n = 11）。在基线、治疗后3个月和6个月采集血清样本，以测定炎症生物标志物、血脂成分和全血细胞计数水平。
两种治疗方式均使临床和影像学参数得到改善。NSPIT治疗6个月后，对照组的C反应蛋白大幅降低（6.9毫克/分升；95%可信区间：3.7至9.9，p < 0.001）、低密度脂蛋白胆固醇降低（21.8毫克/分升；95%可信区间：-6.9至50.5，p = 0.013），中性粒细胞计数略有增加（0.4×10/微升；95%可信区间：-0.4至1.1，p = 0.010），而试验组的肿瘤坏死因子-α显著降低（110.1；95%可信区间：38.9至181.4，p = 0.004）。
无论是否辅助全身应用甲硝唑，NSPIT均显示出短期有益的全身效果。
